SPRB sprucebiosciences.com Net earnings per share for the last 12 months

Public company logo of Spruce Biosciences (SPRB)

Spruce Biosciences (SPRB) enjoys high trust among endocrinologists due to its precise research in the field of adrenal glands. Business growth is driven by tildacerfont trials and high demand within the rare pathology niche. The rolling annual earnings per share clearly demonstrates capital dynamics, where the value -34.83 expresses the state of the metric. The absence of market peers guarantees the company future pricing power and high margins.

SPRB (sprucebiosciences.com) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/13/2026

Analytical breakdowns and data insights for company sprucebiosciences.com (SPRB)

- stock price and consensus target price:
Stock Price Spruce Biosciences|SPRB - Average Forecast Price
- market capitalization data:
Market Valuation Spruce Biosciences, Inc.|SPRB - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Spruce Biosciences|SPRB - Book Capitalization|Market Capitalization to Book Value Ratio sprucebiosciences.com|SPRB - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Spruce Biosciences|SPRB - Long-Term Liabilities to Capital|Short-Term Debt to Equity Spruce Biosciences, Inc.|SPRB - Company Debts|Debts to Book Capitalization Spruce Biosciences, Inc.|SPRB - Long-Term Debt Volume|Company Short-Term Debt Spruce Biosciences|Quick Liquidity sprucebiosciences.com
- net income and valuation multiples indicators:
SPRB - Net Income|Expected Profit Spruce Biosciences|SPRB - Business Payback Period|Future Price to Earnings Spruce Biosciences|SPRB - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Spruce Biosciences, Inc.|SPRB - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Spruce Biosciences|SPRB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth sprucebiosciences.com|SPRB - Net earnings per share growth this year|Earnings growth forecast for next year Spruce Biosciences
- sales and revenue data:
SPRB - Company Total Revenue|Company Future Sales Volume Spruce Biosciences, Inc.|SPRB - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Spruce Biosciences, Inc.
Fundamental company valuation:Spruce Biosciences (SPRB)
Mass-produced product of Spruce Biosciences, Inc.

The specifics of clinical protocol outsourcing at Spruce Biosciences (SPRB) make financial results highly sensitive to external contractor costs. The TTM EPS metric digitizes the final net income allocated per common share over one year. This calculation filters out the noise of one-off transactions, revealing the actual inertia of business profitability. Monitoring changes in per-share profit over the last 12 months allows for the timely detection of capital stagnation.

Competitors of Spruce Biosciences

Ascendis Pharma A/S - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months madrigalpharma.com|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Therapeutics|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (crinetics.com)|Earnings per share for the last twelve months NewAmsterdam Pharma Company N.V. NAMS|Soleno Therapeutics Inc (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx|Rezolute Inc (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Lexicon Pharma (LXRX)|Net earnings per share for the last 12 months MBX Corp MBX|Earnings per share for the last twelve months Altimmune, Inc. ALT|Net earnings per share for the last four quarters aardvarktherapeutics.com (AARD)|SGMT - Earnings per share for the last twelve months|Earnings per one share for the last 12 months BIOA|Biomea (BMEA) - Earnings per share for the last twelve months|Quince Therapeutics, Inc. - Earnings per share for the trailing year|Net earnings per share for the last 12 months GUTS|Net earnings per share (EPS TTM) vTv Therapeutics Inc|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last 12 months pluri-biotech.com PLUR|Net earnings per share (EPS TTM) SYBX (Synlogic)|Lipocine Corporation (LPCN) - Net earnings per one share for the last twelve months|MTNB: Net earnings per share for the last 12 months|Earnings per share for the trailing year GLTO (galecto.com)|CTCX: Net earnings per share (EPS TTM)|LUMO (Lumos Pharma Inc) - Earnings per share for the last twelve months|ONVO (Organovo Holdings Inc) - Net earnings per share (EPS TTM)|Radius Pharmaceuticals (RDUS) - Net earnings per share for the last four quarters